Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
129
天
59
天
190
天
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial
作者
Quoc-Dien Trinh; Daniel J. George; Neal Shore; Egils Vjaters; David Olmos; Andrea Juliana P. de Santana Gomes; Augusto Cesar de Andrade Mota; Natasha Littleton; Shankar Srinivasan; Frank Verholen; Kunhi Parambath Haresh; Fred Saad展开收起
作者单位
1. University of Pittsburgh Medical Center, Pittsburgh, USA; 2. Duke University School of Medicine, Duke Cancer Institute, Durham, USA; 3. Carolina Urologic Research Center and AUC Urology Specialists, Myrtle Beach, USA; 4. P. Stradinš Clinical University Hospital, Riga, Latvia; 5. Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain; 6. Liga Norte Riograndense Contra O Cancer, Natal, Brazil; 7. Medical Oncology, Instituto ETICA – Clinica AMO/DASA, Salvador, Brazil; 8. Bayer Ltd, Dublin, Ireland; 9. Bayer Healthcare, Whippany, USA; 10. Bayer Consumer Care AG, Basel, Switzerland; 11. All India Institute of Medical Sciences, New Delhi, India; 12. University of Montreal Hospital Centre, Montreal, Canada展开收起
72
天
129
天
127
天
Navigating drug–drug interactions with apalutamide
作者
Bilal A. Siddiqui; Karine Tawagi; Sarah Caulfield; Pankaj Aggarwal; Tanya Dorff展开收起
作者单位
1. Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; 2. Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, Chicago, USA; 3. Genitourinary Clinic, Emory Healthcare, Winship Cancer Institute, Atlanta, USA; 4. Johnson & Johnson, Horsham, USA; 5. Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天